Your browser doesn't support javascript.
loading
Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.
Gümüs, Mahmut; Chen, Chieh-I; Ivanescu, Cristina; Kilickap, Saadettin; Bondarenko, Igor; Özgüroglu, Mustafa; Gogishvili, Miranda; Turk, Haci M; Cicin, Irfan; Harnett, James; Mastey, Vera; Naumann, Ulrike; Reaney, Matthew; Konidaris, Gerasimos; Sasane, Medha; Brady, Keri J S; Li, Siyu; Gullo, Giuseppe; Rietschel, Petra; Sezer, Ahmet.
Affiliation
  • Gümüs M; Istanbul Medeniyet University, Faculty of Medicine, Istanbul, Turkey.
  • Chen CI; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.
  • Ivanescu C; IQVIA, Amsterdam, The Netherlands.
  • Kilickap S; Department of Medical Oncology, Istinye University Faculty of Medicine Liv Hospital, Ankara, Turkey.
  • Bondarenko I; Dnipropetrovsk State Medical Academy, City Multifield Clinical Hospital, Dnipropetrovsk, Ukraine.
  • Özgüroglu M; Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  • Gogishvili M; High Technology Medical Centre, Tbilisi, Georgia.
  • Turk HM; Department of Medical Oncology, Bezmialem Vakif University, Medical Faculty, Istanbul, Turkey.
  • Cicin I; Department of Medical Oncology, Trakya University, Iskender/Edirne Merkez/Edirne, Turkey.
  • Harnett J; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.
  • Mastey V; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.
  • Naumann U; IQVIA, Reading, UK.
  • Reaney M; IQVIA, Reading, UK.
  • Konidaris G; Sanofi, Reading, UK.
  • Sasane M; Sanofi, Bridgewater, New Jersey, USA.
  • Brady KJS; Sanofi, Cambridge, Massachusetts, USA.
  • Li S; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.
  • Gullo G; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.
  • Rietschel P; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.
  • Sezer A; Department of Medical Oncology, Baskent University, Etimesgut, Ankara, Turkey.
Cancer ; 129(1): 118-129, 2023 01 01.
Article in En | MEDLINE | ID: mdl-36308296
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized / Antineoplastic Agents, Immunological / Lung Neoplasms Type of study: Prognostic_studies Aspects: Patient_preference Limits: Adult / Humans Language: En Journal: Cancer Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized / Antineoplastic Agents, Immunological / Lung Neoplasms Type of study: Prognostic_studies Aspects: Patient_preference Limits: Adult / Humans Language: En Journal: Cancer Year: 2023 Document type: Article Affiliation country: Country of publication: